Increased nuclear ndrg1 expression in prostate cancer and positively associated with increasing Gleason grade and stage, while decreased membranous and cytoplasmic ndrg1 expression in prostate cancer

Abstract EN

Background : prostate cancer has few prognostic biomarkers, and differential diagnosis and prognosis of aggressive versus non-aggressive tumors can be challenging clinically.

Aims : this study aims to investigate the hypothesis that ndrg1 might be a potential biomarker for prostate tumor and could distinguish between aggressive tumors requiring radical intervention and those that have a good prognosis.

it is thought to be a potential biomarker that can predict the clinical progression and prognosis of different kinds of tumors.

however, its role in prostate cancer remains unclear.

materials and methods : ndrg1 expression has been evaluated by immunohistochemistry using a tissue microarray cohort with 96 cases including normal, adjacent normal and malignant prostate tissues.

results : this study showed nuclear, cytoplasmic and membranous ndrg1 immunostaining in both normal and malignant prostate tissues.

reduction of membranous and increased nucleocytoplasmic ndrg1 staining is shown in prostate cancer compared to normal prostate and is positively associated with increasing primary Gleason grade, but not with clinical stage.

nuclear ndrg1 staining is increased significantly in prostate cancer and is positively associated with increasing primary Gleason grade and clinical stage.

in contrast, cytoplasmic ndrg1 staining is decreased significantly in prostate cancer compared to normal prostate, but not associated with other clinical features.

conclusion : this preliminary data suggests that ndrg1 may have a role in cancer development and/or aggressiveness and warrants further investigation to understand its function and establish if it could be a potential diagnostic biomarker for prostate cancer.